Skip to Content
Morningstar

Dare Bioscience Inc DARE

Morningstar Rating
Unlock
Stock XNAS Rating as of
$0.31 +0.02 (5.77%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
DARE is trading at a 56% discount.
Price
$0.30
Fair Value
$3.50
Uncertainty
Extreme
1-Star Price
$63.47
5-Star Price
$5.64
Economic Moat
Ypz
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DARE is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$0.29
Day Range
$0.28–0.31
52-Week Range
$0.27–1.10
Bid/Ask
$0.30 / $0.31
Market Cap
$30.77 Mil
Volume/Avg
175,076 / 453,516

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
9.51
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women’s health.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
26
Website
https://www.darebioscience.com

Comparables

Valuation

View More
Metric
DARE
SPRY
ARQT
Price/Earnings (Normalized)
 ———
Price/Book Value
 —3.499.38
Price/Sales
 9.51—9.99
Price/Cash Flow
 ———
Price/Earnings
DARE
SPRY
ARQT

Financial Strength

Metric
DARE
SPRY
ARQT
Quick Ratio
 0.5695.846.38
Current Ratio
 0.8696.927.08
Interest Coverage
 ——−7.72
Quick Ratio
DARE
SPRY
ARQT

Profitability

Metric
DARE
SPRY
ARQT
Return on Assets (Normalized)
 −96.11%−17.45%−64.70%
Return on Equity (Normalized)
 −2,291.89%−18.04%−204.18%
Return on Invested Capital (Normalized)
 −1,569.26%−18.02%−65.35%
Return on Assets
DARE
SPRY
ARQT
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTylhfrpvjKryd$554.7 Bil
VRTX
Vertex Pharmaceuticals IncTphdvxxdTmrcw$102.7 Bil
REGN
Regeneron Pharmaceuticals IncHgppvjvhtJzdbf$97.8 Bil
MRNA
Moderna IncQswstlfFftj$41.3 Bil
ARGX
argenx SE ADRSslpczkrGhbdj$22.3 Bil
BNTX
BioNTech SE ADRPyczqbjcsXyyq$21.0 Bil
ALNY
Alnylam Pharmaceuticals IncLvjcsjsBhygyb$18.2 Bil
BMRN
Biomarin Pharmaceutical IncRmbfjflmMccsnt$15.4 Bil
RPRX
Royalty Pharma PLC Class AHnktrkcjFxknjwf$12.5 Bil
INCY
Incyte CorpRcbkfrkyYrmglc$11.6 Bil

Sponsor Center